Cspc Pharmaceutical | 1093

Stock Price
11.19
Daily Change
0.36 3.32%
Monthly
11.23%
Yearly
140.13%
Q3 Forecast
11.09

Peers Price Chg Day Year Date
Cspc Pharmaceutical 11.19 0.36 3.32% 140.13% Sep/05
Sino Biopharmaceutical 8.91 0.52 6.20% 183.76% Sep/05
Avita Medical 1.34 0.01 0.75% -48.46% Sep/05
Sh Fosun Pharma 30.19 0.86 2.93% 34.12% Sep/05
Jiangsu Hengrui 72.47 3.82 5.56% 63.22% Sep/05
Zhangzhou Pientzehuang Pharmaceutical 203.87 0.94 0.46% 0.69% Sep/05
Kangmei Pharma 2.03 0 0% 15.34% Sep/05
WuXi AppTec 107.40 5.46 5.36% 176.80% Sep/05
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
IQVIA Holdings 187.68 3.60 1.96% -22.83% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Organon & Co 10.38 0.70 7.23% -49.40% Sep/05
Revvity 86.64 0.94 1.10% -24.90% Sep/05
Viatris 10.50 0.17 1.65% -6.87% Sep/05
Xeris Pharmaceuticals 7.85 -0.04 -0.51% 212.75% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05

Indexes Price Day Year Date
HK50 25418 359.47 1.43% 47.81% Sep/05

Cspc Pharmaceutical traded at 11.19 this Friday September 5th, increasing 0.36 or 3.32 percent since the previous trading session. Looking back, over the last four weeks, Cspc Pharmaceutical gained 11.23 percent. Over the last 12 months, its price rose by 140.13 percent. Looking ahead, we forecast Cspc Pharmaceutical to be priced at 11.09 by the end of this quarter and at 10.80 in one year, according to Trading Economics global macro models projections and analysts expectations.

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.